About Two River
Two River is a venture capital firm founded in 2004. It is primarily based out of New York City, United States. As of Sep 2024, Two River has invested in 17 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Consumer and Retail. Most recently it participated in the $***** Series D round of Candid Therapeutics Overall, Two River portfolio has seen 4 IPOs and 7 acquisitions including key companies like Kite Pharma, Thirty Madison and UroGen Pharma. A lot of funds co-invest with Two River, with names like Vida Ventures sharing a substantial percentage of its portfolio. Two River has team of 8 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Two River's List of Top Investments
Two River has a portfolio of 17 companies. Their most notable investments are in Hubble Contacts and Hubble Contacts.Their portfolio spans across United States and Israel. They have invested in Life Sciences, Consumer, Retail and 4 other sectors, across stages such as Series A, Seed and 2 more. Here is the list of top investments by Two River:1. Kite Pharma
Developer of cancer immunotherapy products using genetic engineering. The company's product Yescarta a CAR-T therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma and TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Key facts about Kite Pharma
- Founded Year: 2009
- Location: Los Angeles (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $97.7M
- Employee Count: 3,991 as on May 31, 2026
- Investors: Amgen Business Development, Pontifax and 10 Others
- Latest Funding Round: Post IPO, Apr 03, 2018, $*****
- Highlight: Acquired
Healthcare platform offers various brands and personalized treatments. A virtual-first specialized healthcare company that provides virtual care for chronic conditions and specialized brands that focus on specific healthcare needs including Keeps for men's hair loss, Cove for migraine, Picnic for allergies, Facet for skin conditions, and NURX for sexual health.
Key facts about Thirty Madison
- Founded Year: 2017
- Location: New York City (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $210M
- Employee Count: 213 as on May 31, 2026
- Investors: Greycroft, Bracket Capital and 24 Others
- Latest Funding Round: Series C, Jun 02, 2021, $*****
- Highlight: Acquired
Developer of therapeutics to treat urothelial and specialty cancers. The company uses proprietary technology RTGel to deliver targeted therapies which include "Jelmyto" for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer.
Key facts about UroGen Pharma
- Founded Year: 2004
- Location: Ra anana (Israel)
- Stage: Public
- Total Funding till date: $7M
- Employee Count: 327 as on May 31, 2026
- Investors: RTW Investments, Pontifax and 12 Others
- Latest Funding Round: Post IPO, Jul 27, 2023, $*****
- Highlight: Public
_1548135965397.png?format=webp&height=120&width=120){kind=logo}
4. Kronos Bio
Developer of small molecule-based therapeutics for cancer treatment. The company has developed small molecules that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity.
Key facts about Kronos Bio
- Founded Year: 2017
- Location: San Mateo (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $271M
- Employee Count: 52 as on Feb 24, 2025
- Investors: Fidelity Investments, Perceptive Advisors and 18 Others
- Latest Funding Round: Series B, Aug 24, 2020, $*****
- Highlight: Acquired
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Key facts about Candid Therapeutics
- Founded Year: 2024
- Location: San Diego (United States)
- Stage: Acquired
- Total Funding till date: $875M
- Investors: Janus Henderson Investors, Foresite Capital and 19 Others
- Latest Funding Round: Series E, Mar 02, 2026, $*****
- Highlight: Acquired
Two River's Year-on-Year Investment Trends
Two River has invested in 17 companies over the last 10 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Candid Therapeutics and most recent follow-on round was in ByHeart.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 1 | 1 | 2 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
2020 | 1 | 1 | 2 |
2019 | 1 | 0 | 1 |
2018 | 3 | 0 | 3 |
2017 | 0 | 2 | 2 |
Two River's Investments by Stage
Two River has made 5 investments in Series A stage with an average round size of $39M, 3 investments in Seed stage with an average round size of $11.8M, 1 investment in Series B stage with an average round size of $60.6M and 1 investment in Series D stage with an average round size of $370M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Seed | 3 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Two River's Investments by Sector
Two River has a diverse portfolio, with companies operating in the Life Sciences, Consumer, HealthTech, Consumer Goods and Healthcare. Notably, it has invested in 14 Tech companies, 12 Enterprise (B2B) companies, 4 Consumer (B2C) companies and 1 company focusing on Marketplace.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Consumer | 2 |
HealthTech | 2 |
Consumer Goods | 1 |
Healthcare | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Two River's Investments by Geography
Two River has made most investments in United States (10).Two River's recent investments
Two River has not made any investment in 2026 so far.Here are the most recent investments by Two River:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 09, 2024 | United States | Series D | 6091 | [+17] | |
Mar 28, 2024 | United States | Series C | 9326 | [+6] | |
Jul 09, 2021 | United States | Series B | 7436 | [+5] | |
Jan 05, 2021 | United States | Series A | 7550 | [+6] | |
Sep 02, 2020 | United States | Series A | 9130 | [+6] |
IPOs and Publicly Listed companies in Two River's Portfolio
4 of Two River's portfolio companies have become public. Allogene Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2018 and UroGen Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $156M.Here are Two River's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 11, 2018 | - | - | 2695 | |
May 04, 2017 | - | - | 1097 | |
Nov 15, 2011 | - | - | 8860 | |
Feb 26, 2007 | - | - | 2225 |
Acquired companies in Two River's Portfolio
7 companies from Two River's portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are Two River's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 9354 | |
Sep 03, 2025 | Oct 16, 2018 | Series A | 2664 | |
May 01, 2025 | May 23, 2018 | Seed | 1033 | |
Nov 29, 2022 | May 10, 2019 | Seed | 3191 | |
Dec 20, 2021 | Mar 04, 2020 | Series A | 7969 |
_1548135965397.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Two River
Two River has a team of 8 members including 3 Partners, 1 Venture Partner and 1 Principal located in United States. Two River's team does not sit on the board of any company as of now.Here is a list of all team members in Two River:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Los Angeles | - | ||
Partner | - | - | ||
Partner | Franklin Lakes | - | ||
Venture Partner | United States | - | - | |
Principal | New York City | - | - |
Co-investors of Two River
Over the past 10 years, 87 investors have co-invested in Two River's portfolio companies. This includes funds and angels.
- Invested before Two River: Polaris Partners, OCV Partners and 10 others have invested in rounds before Two River. There is 1 company where Polaris Partners has invested before Two River and 1 company where OCV Partners has invested before Two River.
- Top Co-investors of Two River: 47 investors entered a company along with Two River. These include investors like Vida Ventures (4 companies).
- Invested after Two River: A total of 28 investors have invested in Two River's portfolio after their investments. Top Investors include Polaris Partners (3 companies), BlackRock (2 companies) and EcoR1 (2 companies).
Recent News related to Two River
•
•
Candid Therapeutics Debuts With $370m Capital Raise To Clinically Evaluate Potentially Transformative Autoimmune TherapiesBusiness Wire•Sep 09, 2024•Candid, Venrock, Fairmont, TCG Crossover and 16 others
•
Third Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific out of ChinaEndPoints News•Aug 05, 2024•Third Rock Techkno, Two River
•
BYHEART, working in the field of baby nutrition, received an investment of $ 95 millionWebrazzi•May 14, 2024•ByHeart, D1 Capital Partners, Bellco Capital, Polaris Partners and 5 others
•
•
Baby formula company secures $90M in series B fundingThe Business Journals•Jul 26, 2021•ByHeart, OCV Partners, Polaris Partners, Bellco Capital and 4 others
•
Iconovir Bio Raises $77 Million In Series A Financing To Develop Next-generation Oncolytic Viruses To Treat Solid TumorsPipelinereview•Jan 05, 2021•IconOVir, Nextech Systems, Vida Ventures, Two River and 5 others
•
Amsterdam-based Neogene Therapeutics raises $110M Series A funding to treat cancer patients with personalized neo-antigen T cell therapiesTechStartups.com•Sep 14, 2020•Neogene Therapeutics, EcoR1, Jeito, Syncona and 5 others
•
Amunix raises $73m to advance lead candidate to clinicPharma Business International•Mar 06, 2020•Amunix, Frazier Healthcare Partners, Longitude Capital, Redmile Group and 7 others
•
Amunix Raises $73 Million in Series A Financing Led by Omega FundsGlobeNewswire•Mar 04, 2020•Amunix, Omega Funds, Frazier Healthcare Partners, Longitude Capital and 7 others
